Evaluating Drugs to Treat Hemangiosarcoma
Tyrosine kinase inhibitors may have the potential to control the growth of hemangiosarcoma.
Hemangiosarcoma remains one of the deadliest canine cancers. Despite treatments such as chemotherapy, immunotherapy and surgery, dogs rarely live beyond six months after diagnosis. New approaches are needed to improve the survival time of dogs afflicted with this devastating disease.
This study will expand on the team’s previous research into a novel class of drugs – tyrosine kinase inhibitors – that may have the potential to control the growth of hemangiosarcoma. The results will help to clarify abnormalities that contribute to hemangiosarcoma proliferation and may ultimately lead to new treatment options for this aggressive cancer.
Co-sponsored with the Morris Animal Foundation, Grant Number: D08CA-050
Stuart C. Helfand, DVM
Oregon State University